CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 199 filers reported holding CLOVIS ONCOLOGY INC in Q3 2015. The put-call ratio across all filers is 0.94 and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $66,197,000 | +38.8% | 1,490,258 | +12.7% | 0.01% | +20.0% |
Q3 2016 | $47,677,000 | +172.6% | 1,322,514 | +3.8% | 0.01% | +150.0% |
Q2 2016 | $17,487,000 | -24.0% | 1,274,534 | +6.3% | 0.00% | -20.0% |
Q1 2016 | $23,019,000 | -43.0% | 1,198,921 | +3.9% | 0.01% | -44.4% |
Q4 2015 | $40,390,000 | -64.5% | 1,153,986 | -6.6% | 0.01% | -69.0% |
Q3 2015 | $113,652,000 | +24.5% | 1,235,880 | +18.9% | 0.03% | +31.8% |
Q2 2015 | $91,317,000 | +15.4% | 1,039,109 | -2.5% | 0.02% | +15.8% |
Q1 2015 | $79,147,000 | +35.9% | 1,066,240 | +2.6% | 0.02% | +35.7% |
Q4 2014 | $58,221,000 | +33.8% | 1,039,661 | +8.4% | 0.01% | +16.7% |
Q3 2014 | $43,500,000 | +9.6% | 958,991 | +0.1% | 0.01% | +9.1% |
Q2 2014 | $39,675,000 | -33.6% | 958,092 | +11.1% | 0.01% | -38.9% |
Q1 2014 | $59,732,000 | +19.5% | 862,307 | +3.9% | 0.02% | +20.0% |
Q4 2013 | $50,003,000 | +11.1% | 829,654 | +12.1% | 0.02% | 0.0% |
Q3 2013 | $45,013,000 | +20.7% | 740,346 | +32.9% | 0.02% | +7.1% |
Q2 2013 | $37,305,000 | – | 556,957 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |